A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.

A process of synthesizing an N.sup.6-isotope-labeled ergot alkaloid is suggested, comprising: demethylating the ergot alkaloid to obtain a corresponding N.sup.6-demethylated norergot alkaloid; remethylating the corresponding N.sup.6-demethylated norergot alkaloid to obtain the N.sup.6-isotopically labeled ergot alkaloid; wherein remethylating is carried out with an isotopically labeled methylation reagent.

A process of synthesizing an N.sup.6-isotope-labeled ergot alkaloid is suggested, comprising: demethylating the ergot alkaloid to obtain a corresponding N.sup.6-demethylated norergot alkaloid; remethylating the corresponding N.sup.6-demethylated norergot alkaloid to obtain the N.sup.6-isotopically labeled ergot alkaloid; wherein remethylating is carried out with an isotopically labeled methylation reagent.